NO20062496L - Fremgangsmater for behandling av astma - Google Patents
Fremgangsmater for behandling av astmaInfo
- Publication number
- NO20062496L NO20062496L NO20062496A NO20062496A NO20062496L NO 20062496 L NO20062496 L NO 20062496L NO 20062496 A NO20062496 A NO 20062496A NO 20062496 A NO20062496 A NO 20062496A NO 20062496 L NO20062496 L NO 20062496L
- Authority
- NO
- Norway
- Prior art keywords
- pkc
- methods
- protein
- agents
- inhibit
- Prior art date
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/48—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase
- C12Q1/485—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase involving kinase
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/10—Expectorants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
- G01N33/5047—Cells of the immune system
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/12—Pulmonary diseases
- G01N2800/122—Chronic or obstructive airway disorders, e.g. asthma COPD
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Animal Behavior & Ethology (AREA)
- Analytical Chemistry (AREA)
- Pulmonology (AREA)
- Public Health (AREA)
- Cell Biology (AREA)
- Pharmacology & Pharmacy (AREA)
- Biochemistry (AREA)
- Veterinary Medicine (AREA)
- Biotechnology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Microbiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Physics & Mathematics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Toxicology (AREA)
- Tropical Medicine & Parasitology (AREA)
- General Engineering & Computer Science (AREA)
- Biophysics (AREA)
- Otolaryngology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Fremgangsmåter som er anvendelige for behandling av astma er beskrevet. Fremgangsmåtene innbefatter screening med henblikk på midler som hemmer dannelsen av et PKC-?-protein, samt midler som hemmer kinaseaktiviteten av et PKC-?-protein eller et funksjonelt fragment derav, hvor slike midler er anvendelige for behandling av astma. Fremgangsmåtene innbefatter også screening med henblikk på midler som hemmer dannelsen av et rapportørgenprodukt som kodes for av en nukleinsyresekvens som er operabelt bundet til en PKC-?-promoter. Det er også beskrevet fremgangsmåter for behandling av astma, som innbefatter administrering av et middel som hemmer dannelsen av et funksjonelt PKC-?-protein eller kinaseaktiviteten av et PKC-?-protein eller et funksjonelt fragment derav. En isolert mastcelle som mangler ekspresjon av endogen PKC-?, er også beskrevet.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US53252503P | 2003-12-24 | 2003-12-24 | |
US58941504P | 2004-07-20 | 2004-07-20 | |
PCT/US2004/043281 WO2005062918A2 (en) | 2003-12-24 | 2004-12-22 | Methods of treating asthma |
Publications (1)
Publication Number | Publication Date |
---|---|
NO20062496L true NO20062496L (no) | 2006-09-11 |
Family
ID=34743021
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO20062496A NO20062496L (no) | 2003-12-24 | 2006-05-31 | Fremgangsmater for behandling av astma |
Country Status (14)
Country | Link |
---|---|
US (1) | US20050164323A1 (no) |
EP (1) | EP1702214A4 (no) |
JP (1) | JP2007525210A (no) |
KR (1) | KR20060127415A (no) |
AU (1) | AU2004308441A1 (no) |
BR (1) | BRPI0417212A (no) |
CA (1) | CA2545722A1 (no) |
CR (1) | CR8398A (no) |
EC (1) | ECSP066672A (no) |
IL (1) | IL175351A0 (no) |
MX (1) | MXPA06007094A (no) |
NO (1) | NO20062496L (no) |
RU (1) | RU2006126704A (no) |
WO (1) | WO2005062918A2 (no) |
Families Citing this family (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20060258562A1 (en) * | 2000-07-31 | 2006-11-16 | Healor Ltd. | Methods and pharmaceutical compositions for healing wounds |
JP4668902B2 (ja) | 2003-08-07 | 2011-04-13 | ヒーラー リミテッド | 創傷治癒を促進するための薬剤組成物及び方法 |
US7501121B2 (en) | 2004-06-17 | 2009-03-10 | Wyeth | IL-13 binding agents |
AR049390A1 (es) * | 2004-06-09 | 2006-07-26 | Wyeth Corp | Anticuerpos contra la interleuquina-13 humana y usos de los mismos |
US20090098142A1 (en) * | 2004-06-09 | 2009-04-16 | Kasaian Marion T | Methods and compositions for treating and monitoring treatment of IL-13-associated disorders |
DE102005020754B3 (de) * | 2005-05-02 | 2007-01-11 | Altana Pharma Ag | Zelluläres Assayverfahren zur Identifizierung von PKCtheta-Inhibitoren |
NZ566083A (en) * | 2005-08-29 | 2012-11-30 | Healor Ltd | Methods and compositions for prevention and treatment of diabetic and aged skin |
US7883855B2 (en) | 2006-07-21 | 2011-02-08 | Abbott Laboratories | Immunosuppressant drug extraction reagent for immunoassays |
GB0617222D0 (en) * | 2006-08-31 | 2006-10-11 | Vereniging Het Nl Kanker I | Antibiotics |
CA2673314C (en) | 2006-12-29 | 2014-03-11 | Abbott Laboratories | Non-denaturing lysis reagent for use with capture-in-solution immunoassay |
ES2393135T3 (es) | 2006-12-29 | 2012-12-18 | Abbott Laboratories | Ensayo mejorado para fármacos inmunosupresores |
JP5450092B2 (ja) * | 2006-12-29 | 2014-03-26 | アボット・ラボラトリーズ | 全血中の分子または薬物の検出のための診断検査 |
US7914999B2 (en) * | 2006-12-29 | 2011-03-29 | Abbott Laboratories | Non-denaturing lysis reagent |
US20090155784A1 (en) * | 2007-01-22 | 2009-06-18 | Wyeth | Assessment of asthma and allergen-dependent gene expression |
TW200848429A (en) * | 2007-04-23 | 2008-12-16 | Wyeth Corp | Methods and compositions for treating and monitoring treatment of IL-13-associated disorders |
US20100310542A1 (en) * | 2007-07-30 | 2010-12-09 | Healor Ltd. | Pharmaceutical Compositions for treating wouds and related methods |
WO2010017473A2 (en) * | 2008-08-07 | 2010-02-11 | The Salk Institute For Biological Studies | Method of identifying ikk2 activators or inhibitors |
EP2389373B1 (en) | 2009-01-21 | 2017-05-17 | Rigel Pharmaceuticals, Inc. | Derivatives of n2-(3-pyridyl or phenyl)-n4-(4-piperidyl)-2,4-pyrimidinediamine useful in the treatment of inflammatory, autoimmune or proliferative diseases |
EP2507227B1 (en) | 2009-12-01 | 2014-10-08 | Rigel Pharmaceuticals, Inc. | Tetrazolones as protein kinase c inhibitors and uses thereof |
CA2801781C (en) | 2010-07-21 | 2018-02-27 | Rigel Pharmaceuticals, Inc. | Protein kinase c inhibitors and uses thereof |
RU2526146C2 (ru) * | 2012-09-27 | 2014-08-20 | Федеральное государственное бюджетное учреждение "Государственный научный центр "Институт иммунологии" Федерального медико-биологического агентства (ФГБУ "ГНЦ Институт иммунологии" ФМБА России) | Способ профилактики и лечения бронхиальной астмы, осложняющих ее респираторных вирусных инфекций и других воспалительных заболеваний дыхательных путей |
WO2014089112A1 (en) | 2012-12-04 | 2014-06-12 | Rigel Pharmaceuticals, Inc. | Protein kinase c inhibitors and uses thereof |
JP6421170B2 (ja) | 2013-03-14 | 2018-11-07 | ライジェル ファーマシューティカルズ, インコーポレイテッド | プロテインキナーゼc阻害剤およびその使用 |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1994012530A1 (en) * | 1992-11-30 | 1994-06-09 | Biosignal Kutató Fejlesztó Kft. | Polyunsaturated fatty acyl-peptide composition |
US5776716A (en) * | 1994-02-01 | 1998-07-07 | Terrapin Technologies, Inc. | Methods for identifying agents which block the interaction of fyn with PKC-theta, and uses thereof |
US5935803A (en) * | 1994-02-01 | 1999-08-10 | Terrapin Technologies, Inc. | Methods to identify immunomodulators using cognate interaction of PKC-theta |
US6054286A (en) * | 1996-06-18 | 2000-04-25 | Telik, Inc. | Methods to identify immunomodulators using cognate interaction of PKC-theta |
US6040152A (en) * | 1996-12-31 | 2000-03-21 | National Jewish Medical And Research Center | Method and assay for regulation of T cell proliferation |
US6103712A (en) * | 1998-03-05 | 2000-08-15 | Eli Lilly And Company | Therapeutic treatment for asthma |
CA2343934A1 (en) * | 1998-09-25 | 2000-04-06 | The Children's Medical Center Corporation | Short peptides which selectively modulate the activity of protein kinases |
AU2481800A (en) * | 1998-12-17 | 2000-07-03 | La Jolla Institute For Allergy And Immunology | Pkc-interacting cousin of trx (picot) polypeptides, polynucleotides, and methodsof making and using them |
SE9902387D0 (sv) * | 1999-06-22 | 1999-06-22 | Astra Ab | New pharmaceutically active compounds |
US6190869B1 (en) * | 1999-10-26 | 2001-02-20 | Isis Pharmaceuticals, Inc. | Antisense inhibition of protein kinase C-theta expression |
AU2460601A (en) * | 1999-12-27 | 2001-07-09 | La Jolla Institute For Allergy | Methods for identifying agents capable of modulating protein kinase c theta (pkctheta) activity |
-
2004
- 2004-12-22 KR KR1020067012717A patent/KR20060127415A/ko not_active Application Discontinuation
- 2004-12-22 BR BRPI0417212-4A patent/BRPI0417212A/pt not_active IP Right Cessation
- 2004-12-22 AU AU2004308441A patent/AU2004308441A1/en not_active Withdrawn
- 2004-12-22 CA CA002545722A patent/CA2545722A1/en not_active Abandoned
- 2004-12-22 JP JP2006547362A patent/JP2007525210A/ja not_active Withdrawn
- 2004-12-22 EP EP04815366A patent/EP1702214A4/en not_active Withdrawn
- 2004-12-22 US US11/022,327 patent/US20050164323A1/en not_active Abandoned
- 2004-12-22 WO PCT/US2004/043281 patent/WO2005062918A2/en active Application Filing
- 2004-12-22 RU RU2006126704/15A patent/RU2006126704A/ru unknown
- 2004-12-22 MX MXPA06007094A patent/MXPA06007094A/es unknown
-
2006
- 2006-05-01 IL IL175351A patent/IL175351A0/en unknown
- 2006-05-11 CR CR8398A patent/CR8398A/es not_active Application Discontinuation
- 2006-05-31 NO NO20062496A patent/NO20062496L/no not_active Application Discontinuation
- 2006-06-23 EC EC2006006672A patent/ECSP066672A/es unknown
Also Published As
Publication number | Publication date |
---|---|
EP1702214A4 (en) | 2007-12-19 |
BRPI0417212A (pt) | 2007-02-06 |
WO2005062918A3 (en) | 2005-08-25 |
ECSP066672A (es) | 2006-10-25 |
RU2006126704A (ru) | 2008-01-27 |
AU2004308441A1 (en) | 2005-07-14 |
WO2005062918A2 (en) | 2005-07-14 |
MXPA06007094A (es) | 2006-08-23 |
US20050164323A1 (en) | 2005-07-28 |
EP1702214A2 (en) | 2006-09-20 |
KR20060127415A (ko) | 2006-12-12 |
IL175351A0 (en) | 2006-09-05 |
CA2545722A1 (en) | 2005-07-14 |
JP2007525210A (ja) | 2007-09-06 |
CR8398A (es) | 2006-10-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NO20062496L (no) | Fremgangsmater for behandling av astma | |
Cortellino et al. | The base excision repair enzyme MED1 mediates DNA damage response to antitumor drugs and is associated with mismatch repair system integrity | |
Xue et al. | The Ras/phosphatidylinositol 3-kinase and Ras/ERK pathways function as independent survival modules each of which inhibits a distinct apoptotic signaling pathway in sympathetic neurons | |
Fernández-Velasco et al. | TNF-α downregulates transient outward potassium current in rat ventricular myocytes through iNOS overexpression and oxidant species generation | |
NO20092651L (no) | Dihydropyridinderivater som er anvendelige som proteinkinaseinhibitorer | |
WO2007034221A3 (en) | Non small cell lung cancer therapy prognosis and target | |
WO2005030121A3 (en) | Compounds, compositions and methods | |
NO20053112L (no) | Peptider som malsoker tumor- og endotelceller, sammensetninger og anvendelser av slike. | |
KR20140019770A (ko) | 인간 ezh2의 억제제 및 이의 사용 방법 | |
WO2002031134A3 (en) | Novel serine protease genes related to dppiv | |
Opletalova et al. | Correlation of phenotype/genotype in a cohort of 23 xeroderma pigmentosum‐variant patients reveals 12 new disease‐causing POLH mutations | |
EA200801372A1 (ru) | Способы получения замещенных пиримидинов | |
CY1107335T1 (el) | ΝΕΑ ΠΟΛΥΝΟΥΚΛΕΟΤΙΔΙΑ ΚΑΙ ΠΟΛΥΠΕΠΤΙΔΙΑ ΤΟΥ ΓΟΝΙΔΙΟΥ IFNα-17 | |
Tossidou et al. | SUMOylation determines turnover and localization of nephrin at the plasma membrane | |
DK1590467T3 (da) | Anvendelse af regulatoriske sekvenser til specifik, transient ekspression i neuronalt bestemte celler | |
BR112021026531A2 (pt) | Composto, composição farmacêutica, e, método para prevenir ou tratar uma doença mediada pela tirosina cinase 2 | |
Hu et al. | Synthesis of 8-hydroxy-2-iminochromene derivatives as selective and potent inhibitors of human carbonyl reductase 1 | |
NO20060144L (no) | Nye modifiserte corinmolekyler som har substituerte aktiveringssekvenser og anvendelser derav | |
WO2005051331A3 (en) | Chaperone-based therapy for niemann-pick disease | |
WO2006020755A3 (en) | Methods for identifying inhibitors of the mtor pathway as diabetes therapeutics | |
WO2006014490A3 (en) | Polypeptides having alpha-glucosidase activity and polynucleotides encoding same | |
DE602005024442D1 (de) | Wiederherstellung der aktivität von 5-enolpyruvylshikimat-3-phosphat-synthase durch fragmentkomplementierung | |
De La Peña et al. | Inhibition of nonsense-mediated decay induces nociceptive sensitization through activation of the integrated stress response | |
Garbati et al. | Effects on Energy Metabolism of Two Guanidine Molecules,(Boc) 2‐Creatine and Metformin | |
SE0202464D0 (sv) | Use of compounds |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FC2A | Withdrawal, rejection or dismissal of laid open patent application |